Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-03-17

Clinical Trial Update: Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating acalabrutinib in patients with chronic lymphocytic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Acalabrutinib (acalabrutinib)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Chronic Lymphocytic Leukemia- Binet Staging System | Phase 3 | Status: COMPLETED